A rare cause of nephrotic syndrome: Lipoprotein glomerulopathy

Hong Kong Medical Journal

Volumn 15, Issue 1, 2009, Pages 57-60

  Cheung, C Y ^a   Chan, Angel O K ^a   Chan, Y H ^a   Lee, K C ^a   Chan, Gordon P T ^b   Lau, Gene T C ^a   Shek, C C ^a   Chau, K F ^a   Li, C S ^a  

^a QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^b ALICE HO MIU LING NETHERSOLE HOSPITAL   (Hong Kong)

Author keywords

Apolipoproteins E; DNA mutational analysis; Hyperlipoproteinemias; Kidney glomerulus; Lipoproteins

Indexed keywords

APOLIPOPROTEIN E;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DNA DETERMINATION; GENE MUTATION; GLOMERULOPATHY; HONG KONG; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; LABORATORY TEST; LIPOPROTEIN GLOMERULOPATHY; MALE; MUTATIONAL ANALYSIS; NEPHROTIC SYNDROME; PATHOGENESIS; ULTRASOUND;

ADULT; ANTILIPEMIC AGENTS; APOLIPOPROTEINS E; DNA MUTATIONAL ANALYSIS; GLOMERULONEPHRITIS; HONG KONG; HUMANS; LIPOPROTEINS; MALE; MUTATION; NEPHROSIS, LIPOID; NEPHROTIC SYNDROME; POLYMERASE CHAIN REACTION; PROTEINURIA; SIMVASTATIN;

EID: 61849089242     PISSN: 10242708     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Saito T, Sato H, Kudo K, et al. Lipoprotein glomerulopathy: glomerular lipoprotein thrombi in a patient with hyperlipoproteinemia. Am J Kidney Dis 1989;13:148-53.
2. Saito T, Matsunaga A, Oikawa S. Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases. Am J Kidney Dis 2006;47:199-211.
3. Chen HP, Liu ZH, Gong RJ, et al. Lipoprotein glomerulopathy: clinical features and pathological characteristics in Chinese. Chin Med J (Engl) 2004;117:1513-7.
4. Hagiwara M, Yamagata K, Matsunaga T, et al. A novel apolipoprotein E mutation, ApoE Tsukuba (Arg 114 Cys), in lipoprotein glomerulopathy. Nephrol Dial Transplant 2008;23:381-4.
5. Oikawa S, Matsunaga A, Saito T, et al. Apolipoprotein E Sendai (arginine 145→proline): a new variant associated with lipoprotein glomerulopathy. J Am Soc Nephrol 1997;8:820-3.
6. Matsunaga A, Sasaki J, Komatsu T, et al. A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy. Kidney Int 1999;56:421-7.
7. Konishi K, Saruta T, Kuramochi S, et al Association of a novel 3-amino acid deletion mutation of apolipoprotein E (Apo E Tokyo) with lipoprotein glomerulopathy. Nephron 1999;83:214-8.
8. Ando M, Sasaki J, Hua H, et al. A novel 18-amino acid deletion in apolipoprotein E associated with lipoprotein glomerulopathy. Kidney Int 1999;56:1317-23.
9. Sam R, Wu H, Yue L, et al. Lipoprotein glomerulopathy: a new apolipoprotein E mutation with enhanced glomerular binding. Am J Kidney Dis 2006;47:539-48.
10. Kinomura M, Sugiyama H, Saito T, et al. A novel variant apolipoprotein E Okayama in a patient with lipoprotein glomerulopathy. Nephrol Dial Transplant 2008;23:751-6.
11. Rovin BH, Roncone D, McKinley A, Nadasdy T, Korbet SM, Schwartz MM. APOE Kyoto mutation in European Americans with lipoprotein glomerulopathy. N Engl J Med 2007;357:2522-4.
12. Murano T, Matsumura R, Misawa Y, et al. Interaction of endothelial cells and triglyceride-rich lipoproteins with apolipoprotein E (Arg→Cys) from a patient with lipoprotein glomerulopathy. Metabolism 2002;51:201-5.
13. Zhang B, Liu ZH, Zeng CH, Zheng JM, Chen HP, Li LS. Clinicopathological and genetic characteristics in Chinese patients with lipoprotein glomerulopathy. J Nephrol 2008;21:110-7.
14. Luo B, Huang F, Liu Q, et al. Identification of apolipoprotein E Guangzhou (arginine 150 proline), a new variant associated with lipoprotein glomerulopathy. Am J Nephrol 2008;28:347-53.
15. Arai T, Yamashita S, Yamane M, et al. Disappearance of intraglomerular lipoprotein thrombi and marked improvement of nephrotic syndrome by bezafibrate treatment in a patient with lipoprotein glomerulopathy. Atherosclerosis 2003;169:293-9.